HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN

Whitney L. Jackson


17P, Makena, and Preterm Birth: The Controversy Continues

April 26, 2012

A year after the Food and Drug Administration (FDA) quickly and controversially green-lighted the pre-term birth prevention drug Makena® to compete directly with long-used 17P, some arguments have cooled, but the battle for marketplace dominance continues.